Linsley Lab


Personalized medicine, which seeks to match the right drugs to the right patients at the right time, has been most successful in cases where there is a clear genetic linkage between a disease and a therapy. This is not the case for many diseases, including most immune-mediated diseases, which involve more complex genetics and require new approaches for development of personalized therapies.

Our goal is to develop and use cutting edge systems biology approaches to elucidate molecular signatures of complex immune diseases, including autoimmunity and cancer. We expect these signatures to elucidate fundamental mechanisms of disease and response to therapy; new pharmacodynamic, patient stratification, and treatment response biomarkers; and new therapeutic approaches.

Examples of new therapeutic approaches include combination therapies for type 1 diabetes (T1D) predicted from resistance mechanisms and molecular signatures generated by RNA sequencing (RNA-seq) of treated patient whole blood samples.

Peter Linsley

Peter Linsley, PhD

Principal Investigator, Linsley Lab
View Full Bio

Lab Members

Shubham Bansal

Shubham Bansal

Intern, Linsley Lab; Center for Systems Immunology
Brenda Norris

Brenda Norris

Administrative Assistant, Linsley Lab; Center for Systems Immunology
Erin Witkop

Erin Witkop, PhD

Bioinformatics Post Doctoral Research Associate, Linsley Lab; Center for Systems Immunology